AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04773873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFM Crowns on gold coping cast-on
Description: Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
Study NCT04773873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid abutment lithium disilicate crown
Description: Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
Study NCT04773873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid abutment ceramic polymer infiltrated crown
Description: Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
Study NCT01183819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space Fortress
Description: Space Fortress sessions 3 times a week for 12 weeks
Study NCT01183819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic Exercise 4 times a week for 12 weeks
Study NCT01183819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic Exercise 4 times a week for 12 weeks
Study NCT01183819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching/Toning exercise 4 times a week for 12 weeks.
Study NCT01183819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Games
Description: Control games session 3 times a week for 12 weeks
Study NCT02772796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-218
Description: Oral Administration
Study NCT01420627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EZN-2279
Description: Weekly administration of EZN-2279 via IM injection
Study NCT01420627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adagen
Study NCT03635034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insert bladder catheter
Description: Bladder catheter will be inserted according to randomization schema
Study NCT03635034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No catheter
Description: Subjects will not receive a bladder catheter during the ablation procedure
Study NCT01560052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy.
Study NCT04005612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: 300 mg of omega 3-FA once daily for 8 weeks
Study NCT03200496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5206(Fed)
Description: Test drug ll : DA-5206(Fed)
Study NCT03200496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION®
Description: Reference drug : Talion®
Study NCT01076881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT04011462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prewarming 20 minutes
Description: prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
Study NCT04011462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prewarming 30 minutes
Description: prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
Study NCT01076881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Study NCT04002531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General and Neurological examination
Description: Information about your general health, neurological symptoms and current medications with be collected
Study NCT04005612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and omega-3 fatty acid
Description: 50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
Study NCT04002531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vital signs
Description: Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
Study NCT04002531 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 12 lead electrocardiogram
Description: A non-invasive test that measures the electrical activity of the heart
Study NCT04002531 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiogram
Description: A non-invasive sonogram of the heart
Study NCT04002531 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood will be drawn to evaluate general health and renal function (kidney health)
Study NCT04002531 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urine collection
Description: Urine will be collection to evaluate renal function (kidney health)
Study NCT04002531 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 2-hour Holter Monitor
Description: A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
Study NCT04002531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief Pain Inventory questionnaire
Description: A questionnaire about daily pain
Study NCT04002531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life questionnaire
Description: A questionnaire about the impact of disease on their activities of daily living and quality of life
Study NCT00368056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg
Study NCT00368056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT04166435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide + Olaparib
Description: Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
Study NCT06107712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online yoga exercise
Description: The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week.
Study NCT04005612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention
Study NCT04670276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection of emulsified adipose tissue stromal vascular fraction
Description: Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
Study NCT01753557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks
Study NCT01753557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV: 600 - 1000 mg/day based on body weight for 24 weeks
Study NCT01753557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: PEG-IFN alfa-2a: 180mcg/week for 24 weeks
Study NCT01927198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01927198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 5 mg
Study NCT01927198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study NCT01927198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 12.5 mg
Study NCT02437903 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM VOLUMA™ XC
Description: Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
Study NCT02257697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Study NCT02257697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CTX)
Study NCT00636389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux 210H dialyzer
Description: Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
Study NCT00636389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux HD-C4
Description: Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
Study NCT05656261 — intervention group
Intervention type: GENETIC
Intervention: Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
Description: On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
Study NCT02942030 — intervention group
Intervention type: OTHER
Intervention: Computerized assesment battery
Description: All participants will do a computerized assessment battery to identify specific attentional profile
Study NCT03813810 — intervention group
Intervention type: OTHER
Intervention: Non
Description: There would be no interventions. Only measurements will be performed.
Study NCT01824043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab injections
Description: Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
Study NCT03796052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avena Sativa Skincare Regimen
Description: Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
Study NCT03086551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active continuous theta burst stimulation (cTBS)
Description: Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
Study NCT03086551 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sham) continuous theta burst stimulation
Description: Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
Study NCT03086551 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Practice
Description: Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
Study NCT03086551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Practice
Description: Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
Study NCT04831424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier social stress test
Description: The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
Study NCT01653912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 in combination with carboplatin and paclitaxel
Description: Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
Study NCT00591981 — intervention group
Intervention type: BEHAVIORAL
Intervention: TOGA Tools
Description: ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
Study NCT01159080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine dose tacrolimus and less myfortic
Description: oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
Study NCT01159080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced dose tacrolimus and conventional myfortic
Description: low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
Study NCT01703624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA
Study NCT01703624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA
Study NCT01935518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
Study NCT02032056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (10^9 CFU/day)
Study NCT02032056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (10^8 CFU/day)
Study NCT02032056 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00368017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg once a day for 12 weeks
Study NCT03162614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sporozoite-infected mosquitoes challenge.
Description: Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs.
Study NCT03162614 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sporozoite-infected mosquitoes challenge.
Description: Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs.
Study NCT00368017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill once a day for 12 weeks
Study NCT02630979 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measuring satisfaction, knowledge and bias
Description: Questionnaire based assessment.
Study NCT06344585 — intervention group
Intervention type: OTHER
Intervention: Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation
Description: A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries.
Study NCT05018546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation force
Description: RIRS with different irrigation force
Study NCT03281395 — intervention group
Intervention type: PROCEDURE
Intervention: Rapid ventricular pacing (RVP)
Description: Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
Study NCT03281395 — intervention group
Intervention type: PROCEDURE
Intervention: No rapid ventricular pacing
Study NCT01560052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy
Study NCT02819960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probio-Tec® BG-VCap-6.5
Description: Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate